SCHEMBL1752291

SCHEMBL1752291

CNC(=O)OC1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL966301 0.95 EPHX1 (0.59)
SCHEMBL19312134 0.93 EPHX1 (0.62)
Hydrochloric Acid SCHEMBL28201975 0.93 EPHX1 (0.57)
SCHEMBL967500 0.93 EPHX1 (0.62)
SCHEMBL16230019 0.93 EPHX1 (0.62)
SCHEMBL8391708 0.93 EPHX1 (0.62)
SCHEMBL24268428 0.92 EPHX1 (0.47)
SCHEMBL10810342 0.90 EPHX1 (0.47)
SCHEMBL103736 0.90
Hydrochloric Acid SCHEMBL28974203 0.88

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2903979-B1 NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES INHIBIKASE THERAPEUTICS INC (US) 2020-08-19 EP claimed
CN-113292535-B Method for preparing apaluamide intermediate and apaluamide 南京方生和医药科技有限公司 2022-07-01 CN disclosed
CN-113993519-A Degradation agent for cyclin dependent kinase 12(CDK12) and use thereof 达纳-法伯癌症研究公司 2022-01-28 CN disclosed
CN-113292535-A Method for preparing apaluamide intermediate and apaluamide 南京方生和医药科技有限公司 2021-08-24 CN disclosed
CN-110049979-A BROMODOMAIN INHIBITORS 艾伯维公司 2019-07-23 CN disclosed
CN-104507910-B Partially saturated nitrogen-containing heterocyclic compound 大正制药株式会社 2016-06-15 CN disclosed
CN-104507910-A Partially saturated nitrogen-containing heterocyclic compound TAISHO PHARMACEUTICAL CO LTD 2015-04-08 CN disclosed
US-8906852-B2 Inhibitors of protein tyrosine kinase activity METHYLGENE INC. (CA) 2014-12-09 US disclosed
US-20140315801-A1 METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC (CA) 2014-10-23 US disclosed
US-20140179632-A1 METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC. (CA) 2014-06-26 US disclosed
US-20080146643-A1 COMBINATION PFIZER LIMITED (GB) 2008-06-19 US disclosed
WO-2008072053-A2 SUBSTITUTED ARYLPYRAZOLES PFIZER LIMITED (GB) 2008-06-19 WO disclosed
WO-2008072077-A2 COMBINATION OF 1-ARYL-4-CYCLOPROPYLPYRAZOLES WITH ANTHELMINTIC AGENT FOR PARASITIC INFESTATION PFIZER LIMITED (GB) 2008-06-19 WO disclosed
EP-1893581-A1 SUBSTITUTED ARYLPYRAZOLES FOR USE AGAINST PARASITITES Pfizer Limited (GB) 2008-03-05 EP disclosed
US-20070149464-A1 COMBINATION PFIZER INC. (US) 2007-06-28 US disclosed
US-20070149550-A1 1-aryl-4-cyclopropylpyrazoles with at least one fluorine attached to the cyclopropyl ring; parasiticides; fleas; extended duration of action for at least 28 days PFIZER INC. (US) 2007-06-28 US disclosed
US-20060287365-A1 Substituted arylpyrazoles ZOETIS LLC 2006-12-21 US disclosed
WO-2006134468-A1 SUBSTITUTED ARYLPYRAZOLES FOR USE AGAINST PARASITITES PFIZER LIMITED (GB) 2006-12-21 WO disclosed
US-5864043-A CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST KARL THOMAE GMBH (DE) 1999-01-26 US disclosed
US-5541229-A ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS DR. KARL THOMAE GMBH (DE) 1996-07-30 US disclosed